These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29698150)

  • 1. An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate Health State Values in the United Arab Emirates.
    Papadimitropoulos EA; Elbarazi I; Blair I; Katsaiti MS; Shah KK; Devlin NJ
    Value Health Reg Issues; 2015 Sep; 7():34-41. PubMed ID: 29698150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
    Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
    Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
    Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
    Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
    Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
    Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies.
    Shah K; Mulhern B; Longworth L; Janssen MF
    Value Health; 2016 Jan; 19(1):53-9. PubMed ID: 26797236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
    Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
    Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
    Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
    Cole A; Shah K; Mulhern B; Feng Y; Devlin N
    Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valuation of the EQ-5D-5L in Taiwan.
    Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
    PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating an EQ-5D-5L Value Set for China.
    Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K
    Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Indonesian EQ-5D-5L Value Set.
    Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Ramos-Goñi JM; Passchier J; Busschbach JJV
    Pharmacoeconomics; 2017 Nov; 35(11):1153-1165. PubMed ID: 28695543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EQ-5D-5L valuation study in Korea.
    Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
    Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.